Claims an editorial in CMAJ.

Rajendra Kale, interim Editor-in-Chief, CMAJ. ‘This evil devalues females. How can it become curbed? The solution can be to postpone the disclosure of medically irrelevant information to females until after about 30 weeks of being pregnant.’ Related StoriesYale doctor scientist develops brand-new app that aims to decrease pregnancy lossWeb-based app assists females to maintain good health a long time before pregnancyResearchers develop accurate solution to predict postpartum diabetes’A pregnant female being informed the sex of the fetus at ultrasonography at a time when an unquestioned abortion can be done is the starting place of female feticide from a healthcare perspective,’ writes Dr.The development program is co-funded, with POZEN in charge of the US development program and for regulatory filings in america. AstraZeneca offers responsibility for all advancement actions and regulatory filings beyond the US. AstraZeneca provides responsibility for all areas of manufacturing, marketing, distribution and sales on an internationally basis. Both ongoing celebrations will contribute scientific, development and regulatory knowledge to the collaboration. The patent for PN400 expires in 2023 in the usa. AstraZeneca is very happy to announce that people are progressing PN 400 into phase III medical advancement in collaboration with POZEN. Thousands of people worldwide have problems with arthritis and we have been excited about the chance of developing and getting an important fresh therapy to these sufferers.